Weight Loss With Topiramate and Phentermine Combination Therapy in a Patient With Bardet-Biedl Syndrome
Open Access
- 17 July 2025
- journal article
- case report
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (9) , luaf164
Abstract
There is limited data on the effect of antiobesity medications in individuals with Bardet-Biedl syndrome (BBS). Here, we present a case of an adult with BBS who experienced significant weight loss following treatment with a combination of topiramate and phentermine. A 31-year-old female with BBS, with homozygous pathogenic variant in the BBS2 gene, presented with obesity, dyslipidemia, and obstructive sleep apnea. At 29 years of age, her body mass index (BMI) was 43.3 kg/m2 (reference range 18.5-24.9 kg/m2), and she was initiated on 50 mg topiramate daily for migraine prophylaxis. With lifestyle modifications, BMI dropped to 40.5 kg/m2. Subsequently, phentermine 30 mg daily was added. Eight months after adding phentermine, BMI significantly decreased to 31.5 kg/m² (27% decrease in BMI), with improvement in glycemic and lipid parameters. She developed paranoia due to a social stressor prompting a brief hold of phentermine and resumption at a lower dose. This case highlights the weight loss response with phentermine and topiramate combination therapy in a patient with BBS. Further research is needed to explore the efficacy and safety of conventional antiobesity medications in isolation, as sequential or combination therapy to setmelanotide, to most effectively impact weight and metabolic burden in patients with BBS.Keywords
This publication has 15 references indexed in Scilit:
- Anti-obesity drug discovery: advances and challengesNature Reviews Drug Discovery, 2021
- Three- and six-month efficacy and safety of phentermine in a Mexican obese populationInt. Journal of Clinical Pharmacology and Therapeutics, 2021
- Recurrent Psychosis after Phentermine Administration in a Young Female: A Case ReportClinical Psychopharmacology and Neuroscience, 2019
- Cardiovascular Safety During and After Use of Phentermine and TopiramateThe Journal of Clinical Endocrinology & Metabolism, 2018
- Phentermine and topiramate for the management of obesity: a reviewDrug Design, Development and Therapy, 2013
- Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)Obesity, 2012
- How Physician Obesity Specialists Use Drugs to Treat ObesityObesity, 2009
- Efficacy and Safety of Topiramate in the Treatment of Obese Subjects With Essential HypertensionThe American Journal of Cardiology, 2005
- Long-Term Pharmacologic Treatment of Morbid Obesity in a Community PracticeEndocrine Practice, 1997
- Comparison of continuous and intermittent anorectic therapy in obesity.BMJ, 1968